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ABSTRACT
Background: Programmed death-1 (PD-1) is a marker for human neoplastic T cells. Here, we evaluated
whether or not PD-1 was also a marker for human mastocytosis, and explored the role of PD-1 in human mas-
tocytosis cells.
Methods: Immunohistochemical analysis was used to evaluate the expression of PD-1 in clinical samples of
human cutaneous mastocytosis. The expression of PD-1 in human mastocytosis cell lines was checked by RT-
PCR, western blotting and flow cytometry. We stimulated human mastocytosis cell lines (LAD2 and HMC1.2)
with recombinant ligand for PD-1, PD-L1 (rPD-L1), and tested the proliferative activity and the status of signal
molecules by Cell Counting Kit-8 and ELISA, respectively.
Results: Ten of 30 human cutaneous mastocytosis cases (33.3%) expressed PD-1 protein. We also found
that a human mastocytosis line LAD2 cells expressed PD-1 protein on their surfaces. The administration with
rPD-L1 suppressed the stem cell factor-dependent growth of the LAD2 cells. And, rPD-L1 activated SHP-1 and
SHP-2 simultaneously, and decreased the phosphorylation of AKT, in LAD2 cells. In contrast, we could not de-
tect the expression of PD-1, and the significant effect of rPD-L1 on the mutated KIT-driven growth of HMC1.2
cells.
Conclusions: PD-1 could be a marker for human cutaneous mastocytosis and regulate the growth of human
PD-1-positive mastocytosis cells.
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INTRODUCTION
Programmed death-1 (PD-1CD279) is a membrane-
bound type receptor, belonging to CD28CTLA-4
family.1 PD-1 - deficient mice developed lupus-like
autoimmune diseases,2 and PD-1 is known to play im-
portant roles in the regulation of immune systems.
PD-L1 (B7-H1CD274) and PD-L2 (B7-DCCD273)
are shown to be ligands for PD-1.1 PD-1 transduces
inhibitory signals into the cells when interacted with
these ligands.1 The PD-1’s inhibitory signals are
mainly mediated by Src homology 2 domain-
containing tyrosine phosphatase (SHP)-1 andor
SHP-2.3 The expression of PD-1 is observed in both
non-neoplastic T and non-neoplastic B cells.1 Interest-
ingly, only T lymphoproliferative disorders are posi-
tive for PD-1 immunohistochemically, but B lym-
phoproliferative disorders are negative.4-6 Therefore,
PD-1 is utilized to discriminate between T lymphopro-
liferative disorders and B lymphoproliferative disor-
ders in pathological examination. To our knowledge,
there is no report whether or not PD-1 expresses on
another hematoproliferative disorder, mastocytosis.
Mastocytosis is occurred by dysregulating prolif-
eration of mast cells.6 The activation of KIT (CD117)
by its ligand, stem cell factor (SCF, Steel factorKIT
ligand) is critical for the growth, development, and
survival of mast cells.7 Gain of function mutations in
KIT, especially D816V, is shown to cause human
mastocytosis.8,9 Therefore, inhibition of KIT signals
should be therapeutic for this neoplastic disorder.10
One of the promising methods for this purpose is the
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Table　1　Characteristics of patients with cutaneous masto-
cytosis
Case Gender Age PD-1 expression
 1 Female  0 Positive
 2 Male 63 Negative
 3 Female 30 Negative
 4 Male 64 Negative
 5 Male  1 Negative
 6 Male 39 Negative
 7 Male 21 Negative
 8 Female 47 Positive
 9 Male  0 Positive
10 Female  1 Negative
11 Female  0 Positive
12 Female  0 Negative
13 Female  0 Positive
14 Male  0 Positive
15 Female  1 Negative
16 Male 63 Negative
17 Male  3 Positive
18 Female 46 Negative
19 Female  2 Negative
20 Female  3 Positive
21 Female  0 Positive
22 Male  0 Negative
23 Male  1 Negative
24 Male  2 Negative
25 Male  1 Positive
26 Female  0 Negative
27 Female  1 Negative
28 Male  1 Negative
29 Male 72 Negative
30 Female  1 Negative
stimulation of inhibitory receptors on human masto-
cytosis cells.11 The inhibitory receptors are mostly
containing immunoreceptor tyrosine-based inhibitory
(ITIM) motifs within their cytosolic domains.11 When
the receptors were activated, the non-receptor protein
phosphatases, such as Src homology 2 domain-
containing tyrosine phosphatase (SHP)-1 or SHP-2,
were recruited to the ITIMs and activated followed by
reversing the action of tyrosine kinase cascades.11
Some receptors, including CD72, FcγRIIB, Siglecs,
mast cell function-associated antigen, signal regula-
tory protein α, and leukocyte Ig-like receptor B4 (for-
merly gp49B1), paired Ig-like receptor-B, myeloid-
associated immunoglobulin-like receptor I, allergin-1,
CD200 receptor, CD300a, and CD84, have been re-
ported their capacities to down-regulate KIT signals
on human neoplastic or non-neoplastic cells.11-14 PD-1
is also categorized as an inhibitory receptor, and ex-
pected its potential to regulate human mastocytosis
cells.
METHODS
PATIENTS
For studies conducted at Kyoto University Hospital
and Kyoto City Hospital, skin biopsy samples were
obtained from 30 patients diagnosed as cutaneous
mastocytosis (Table 1), and 22 patients diagnosed as
non-specific dermatitis (non-mastocytosis). We ob-
tained informed consent from patients at each hospi-
tal. The methods were approved by the ethical review
committee of each hospital.
CELLS
The human LAD2 mastocytosis cell line was cultured
in StemPro-34 medium, with supplement, containing
L-glutamine (2 mM), penicillin (100 unitsml), strep-
tomycin (100 μgml), and recombinant human
SCF (100 ngml, Peprotech).15 HMC1.2 (expresses
V560G and D816V KIT) human mastocytosis cell
lines were grown in IMDM medium supplemented
with FBS (10%), L-glutamine (2 mM), penicillin (100
unitsml), and streptomycin (100 μgml).9,16
The 293T and the Jurkat cell lines were purchased
from American Type Culture Collection (Manassas,
VA, USA), and grown in RPMI1640 medium supple-
mented with FBS (10%), L-glutamine (2 mM), penicil-
lin (100 unitsml), and streptomycin (100 μgml).
ANTIBODIES AND RECOMBINANT PROTEINS
Anti-human PD-1 antibody (Ab) (mouse monoclonal,
clone: J105) was purchased from eBioscience (San
Diego, CA, USA). The secondary Abs were peroxi-
dase-labeled anti-rabbit or anti-mouse immunoglobu-
lin (Ig) G antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA, USA).
Recombinant human PD-L1Fc chimera (rPD-L1)
protein was purchased from R&D Systems (Minnea-
polis, MN, USA). For the stimulation on the cells,
rPD-L1 was bound to protein G-sepharose, modified
the method of Reference 17.
IMMUNOHISTOCHEMICAL ANALYSIS
Immunohistochemistry was executed as previously
reported.18 After deparaffinization with xylene, tissue
sections were rehydrated and pretreated with 0.3%
hydrogen peroxide for 5 min. After steam heat for 40
min, anti-human PD-1 Ab was added as primary anti-
body for overnight at 4℃. Staining was performed us-
ing the ENVISION kit (DAKO Cytomation, Glostrup,
Denmark) by the manufacturer’s instructions. We
evaluated immunostaining using peripheral T lym-
phoma cells as positive control for PD-1 staining.4,5
Mastocytosis cells in all examined specimens were
reacted to anti-PD-1 antibody in all-or-none pattern.
FLOW CYTOMETRY
For the detection of PD-1 expression, LAD2 or HMC1
cells were washed, and fixed by 4% paraformaldehyde
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(Sigma-Aldrich, St. Louis, MO, USA). The cells were
stained with anti-human PD-1 for overnight at 4℃ fol-
lowed by anti-mouse IgG-FITC for 2 hours at 4℃.
The cells were then analyzed using a FACScan flow
cytometer.
RT-PCR
Total RNA was extracted from 5 × 105 cells (LAD2,
HMC1.2, Jurkat and 293T). Cells were lysed with Tri-
zol (Invitrogen, Carlsbad, CA, USA) and total RNA
was extracted using Rneasy Mini Kit (Qiagen, Valen-
cia, CA, USA). cDNA was synthesized and amplified
using SuperScript III One-Step RT-PCR System, ac-
cording to the manufacturer’s instructions (Invitro-
gen). One ug of RNA was used for cDNA synthesis.
Human PD-1 was amplified using the primers 5’-GAC
AACGCCACCTTCACCT-3’, and 5’-GCTTGTCCGTC
TGGTTGCT-3’.19 cDNA synthesis and PCR amplifica-
tion were executed suing a TaKaRa PCR Thermal
Cycler Dice Standard (TaKaRa, Kyoto, Japan) with
the following thermal cycle protocol. 50℃ for 30 min,
95℃ for 2 min followed by 40 cycles of 95℃ for 30s,
55℃ for 1 min, 72℃ for 1 min and a final extension of
10 min at 72℃.
CELL GROWTH ASSAY
The Cell Counting Kit-8 (CCK-8; Dojindo, Ku-
mamoto, Japan) was used for the evaluation of the
growth of LAD2 and HMC1 cells. The cells were re-
cultured for 24 hours at 2 × 104 cells100 μl of RPMI
1640 + 10% FCS in 96-well plates in the presence or
absence of beads-conjugated rPD-L1 or control IgG
(10 μgml, each). We added 10 μl of CCK-8 solution
for the last 2 hours and estimated the absorbance of
450 nm, according to the manufacturer’s instructions.
ELISA ASSAY FOR SIGNAL MOLECULES
LAD2 were incubated in cytokine-free medium for
overnight, and re-cultured with medium containing
rSCF (10 ngml) in the presence of beads-conjugated
rPD-L1 or control IgG (10 μgml, each) for 15 min-
utes at 37℃. In other experiments, HMC1 were re-
cultured without rSCF (10 ngml) in the presence of
rPD-L1 or control beads for 15 minutes at 37℃. The
cells were collected with beads, and re-suspended in
lysis buffer containing 150 mM NaCl, 10 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 1 mM Na3VO4, 0.5 mM
PMSF, 5 μgml aprotinin, 5 μgml leupeptin, com-
plete protease inhibitor cocktails (Roche, Indianapo-
lis, IN, USA), and 1% NP-40. The samples were as-
sayed for phospho-AKT, phospho-MEK1, phospho-
JNK, phospho-p38, phospho-STAT3, phospho-NF-κB
(Cell Signalling Technology, Beverly, MA, USA, re-
spectively), phospho-SHP-1 or phospho-SHP-2 (R&D
Systems, respectively) using an ELISA kit, according
to the manufacturer’s instructions.
STATISTICAL ANALYSIS
Data were expressed as the means +- SE. A P value
less than 0.05 indicated statistical significance (Excel:
Microsoft, Redmond, WA, USA).
RESULTS
IMMUNOHISTOCHEMICAL ANALYSIS ON HU-
MAN CUTANEOUS MASTOCYTOSIS
PD-1 is known as human neoplastic T cell marker in
clinical pathological field.4,5 Here, we tested whether
or not PD-1 could also be a marker for human cutane-
ous mastocytosis samples. We collected the patho-
logical specimens diagnosed as cutaneous mastocyto-
sis, and executed immunohistochemical analysis.
Anti-PD-1 was reacted to 10 of 30 cases (33.3%) diag-
nosed as cutaneous mastocytosis (Table 1, Fig. 1),
though PD-1 was undetectable in all-examined non-
mastocytosis mast cells, including the samples diag-
nosed as non-specific dermatitis (Fig. 1).
PD-1 EXPRESSION ON HUMAN CULTURED
MASTOCYTOSIS CELLS
We also explored PD-1 expression on human masto-
cytosis cell lines, LAD2 and HMC1.2. LAD2 cells ex-
press normal KIT,15 and HMC1.2 has gain-of-function
type mutation in KIT gene.9,16 RT-PCR analysis
showed the expression of PD-1 mRNA in LAD2 (Fig.
2A). FACS analysis also revealed the expression of
PD-1 in LAD2 (Fig. 2B). We could detect PD-1 mRNA
at the very lower level in, but could not PD-1 protein
on HMC1.2 (Fig. 2A, B).
THE PD-1’S EFFECT ON THE GROWTH OF HU-
MAN CULTURED MASTOCYTOSIS CELLS
PD-1 plays inhibitory roles in the growth of human T
cells.1 We tried to determine the PD-1’s effect on the
growth of LAD2 (PD-1-positive) and HMC1 (PD-1-
negative). To stimulate PD-1, we used recombinant
PD-L1 (rPD-L1) conjugated with beads.17 The admini-
stration with rPD-L1 was significantly suppressed
SCF-induced growth of LAD2 cells (Fig. 3A), but did
not mutated KIT-driven growth of HMC1.2 cells (Fig.
3B).
THE PD-1’S EFFECT ON THE SIGNAL MOLE-
CULES OF HUMAN CULTURED MASTOCYTOSIS
CELLS
To elucidate the PD-1’s inhibitory effect on LAD2, we
screened the status of signal molecules of LAD2
stimulated with rPD-L1. The ELISA assay kits were
utilized. The stimulation with rPD-L1 for 15 minutes
declined SCF-induced phospho-AKT, when compared
to the case stimulated with SCF solo (Fig. 4), but did
not phospho-MEK1 (surrogate marker for ERK),
phospho-JNK, phospho-STAT3, and phospho-NF-κB
(Fig. 4).
SHP-1 and SHP-2 are reported to be involved in the
inhibitory effects of PD-1.3 SHP-1 and SHP-2 were ac-
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Fig.　1　PD-1 is expressed by human cutaneous mastocytosis cells. Representive cases of immuno-
histochemical staining for PD-1 (Bars; 50 μm). Ten of 30 cases with cutaneous masytocytosis were 
positive for PD-1, immunohistochemically. The all-examined non-mastocytosis cells including the 
samples diagnosed as non-specifi c dermatitis were not stained by anti-PD-1 antibody.
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Fig.　2　PD-1 is expressed by human mastocytosis cell 
lines. (A) RT-PCR and (B) Flow cytometry were performed 
as described in Methods. The Jurkat cells were used as a 
positive control, and the 293T cells as a negative control.
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tivated by being phosphorylated their C-terminal
tails,20 therefore we used an ELISA kit for phospho-
SHP-1 and for phospho-SHP-2. The administration
with rPD-L1 combined with SCF induced both
phospho-SHP-1 and phospho-SHP-2 in LAD2 cells
(Fig. 4).
DISCUSSION
Here, we found the expression of PD-1 in some mas-
tocytosis cells included in clinical samples diagnosed
as cutaneous mastocytosis and cultured in vitro, and
the inhibitory role of this protein on human mastocy-
tosis cells.
Our immunohistochemical analysis detected the
expression of PD-1 on human cutaneous mastocyto-
sis, but did not on non-neoplastic mast cells. We de-
tected the very weak expression of PD-1 on human
cultured mast cells derived from healthy volunteers21
(data not shown), therefore we suspected the PD-1’s
expression on non-mastocytosis cells in clinical sam-
ples too weakly to be detected by the immunohisto-
chemical analysis.
We analyzed the role of PD-1 using human masto-
cytosis cell lines, and found the PD-1’s inhibitory
roles in LAD2 expressing PD-1 (Fig. 3A). The PD-1’s
inhibitory function in T cells is mediated by SHP-1
andor SHP-2.3,4 In LAD2, both SHP-1 and SHP-2
were activated by the stimulation on PD-1 (Fig. 4).
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Fig.　3　The stimulation on PD-1 with recombinant PD-L1 suppresses the growth of LAD2 
cells, but dose not that of HMC1 cells. The cells were incubated for 24 hours with beads-
conjugated control IgG or rPD-L1. The Cell Counting Kit-8 was used for the evaluation of 
the growth of the cells (n = 4), according to the manufacturer’s protocol. (A) LAD2. (B) 
HMC1.2. *P < 0.05, when compared with the value of vehicle.
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Fig.　4　The administration with rPD-L1 down-regulated the phosphorylation of 
AKT, and induced the phosphorylations of SHP-1 and SHP-2 in LAD2 cells. After 
rPD-L1 was administrated for 15 minutes, the cells were collected. The cell lysates 
were evaluated by the ELISA kit. ELISA for phospho-AKT, phospho-MEK1, phos-
pho-JNK, phospho-STAT3, phospho-NF-κB, phospho-SHP-1 and phospho-SHP-2. 
*P < 0.05, when compared with the value of vehicle.
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Signal analysis revealed the decreased phospho-AKT
(Fig. 4). PI3K - AKT signals play pivotal role of the
growth of human mast cells,22 therefore down-
regulated AKT would be sufficient for the suppres-
sion of LAD2 growth. SHP-1 activation without SHP-2
activation could not suppress PI3K - AKT signals in
human mast cells,13 and we thought the dual activa-
tion of SHP-1 and SHP-2 seemed to be necessary for
the suppression of activation of AKT in LAD2.
To our knowledge, there is no report on the PD-1’s
expression on human mast cells, though there is a re-
port on the expression of the ligands for PD-1 in
mouse mast cells.23 PD-L1 or PD-L2 expression on
human mastocytosis cells was explored. We could
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not detect the expression of PD-L1 or PD-L2 in LAD2
by flow cytometry (data not shown), and could not
observe the significant effect of the antibodies which
inhibited the PD-1 - PD-L1 interaction on the LAD2’s
growth (data not shown). HMC1.2 was confirmed its
expression of PD-L1 and PD-L2. The growth of HMC
1.2 was not influenced by the administration with
anti-PD-1 blocking antibody (data not shown). It
would be owing to the deficient expression of PD-1
(Fig. 2A, B). The effect of intracellular PD-1 - PD-L1
interaction could be excluded among LAD2 cells or
HMC1.2 cells in our in vitro study (Fig. 3A, B).
Currently, anti-PD-1 antibodies have been tested
for the treatment of neoplastic and autoimmune dis-
eases.24-26 Our study seems to suggest that such anti-
bodies could affected on human mastocytosis cells.
Side effect via mastocytosis cells should be consid-
ered when using the anti-PD-1 antibodies.
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